drugset
drugset / Trial / NCT01622088

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088 ↗

Phase 3 Terminated 616 enrolled Knopp Biosciences Biogen · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.

Timeline

Start
2012-06
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 150 mg Oral

Indications

amyotrophic lateral sclerosis